Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Проспективное краткосрочное наблюдательное исследование эффекта комплекса глюкозамина с хондропротекторами у взрослых с диагностированным остеоартритом коленного и/или тазобедренного сустава
Проспективное краткосрочное наблюдательное исследование эффекта комплекса глюкозамина с хондропротекторами у взрослых с диагностированным остеоартритом коленного и/или тазобедренного сустава
Puce M, Medne-Simsone A, Sprudza KL. Проспективное краткосрочное наблюдательное исследование эффекта комплекса глюкозамина с хондропротекторами у взрослых с диагностированным остеоартритом коленного и/или тазобедренного сустава. Consilium Medicum. 2025;27(11):686–696. DOI: 10.26442/20751753.2025.11.203425
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Цель. Остеоартрит (ОА) коленного и/или тазобедренного сустава является хроническим дегенеративным заболеванием, которое оказывает значительное влияние на качество жизни. Современные методы лечения, такие как нестероидные противовоспалительные препараты (НПВП), обеспечивают лишь облегчение симптомов и могут вызывать значительные побочные эффекты. Настоящее исследование проводится с целью оценки того, может ли краткосрочный прием комплекса глюкозамина (глюкозамин, хондроитин, гиалуроновая кислота, омега-3 жирные кислоты, коллаген II типа) облегчить симптомы ОА.
Материалы и методы. В проспективном наблюдательном исследовании приняли участие 200 пациентов с ОА, наблюдаемых у семейных врачей в Латвии. Пациенты были разделены на: 1) исследуемую группу (n=100), получавшую Артроверон® 5в1 КОМПЛЕКС С ОМЕГА-3 (глюкозамина гидрохлорид 300 мг, омега-3 жирные кислоты 100 мг, хондроитина сульфат 50 мг, гиалуроновая кислота 20 мг, коллаген II типа 20 мг); 2) контрольную группу (n=100), не получавшую хондропротекторы. Уровень боли оценивали на исходном уровне и через 30 дней с использованием: индекса ОА университетов Западного Онтарио и Макмастера (WOMAC), Визуальной аналоговой шкалы.
Результаты. В исследуемой группе (принимавшей глюкозаминовый комплекс) отмечено статистически значимое снижение показателей боли по сравнению с контрольной группой (p<0,001). Оценка боли по WOMAC снизилась с 7,3±3,8 до 6,0±3,6 (p<0,001). Оценка скованности по WOMAC улучшилась с 3,4±1,7 до 2,6±1,8 (p<0,001). Оценка затрудненности движений по WOMAC снизилась с 26,6±11,3 до 21,0±11,5 (p<0,001). Оценка боли по Визуальной аналоговой шкале снизилась с 5,8±1,6 до 4,9±1,5 в исследуемой группе, а в контрольной группе – с 4,8±1,8 до 4,2±2,0 (p<0,001).
Заключение. Краткосрочное применение добавки Артроверон® 5в1 КОМПЛЕКС С ОМЕГА-3 значительно уменьшило боль и скованность при ОА по сравнению с контрольной группой, не получавшей лечения. Эти результаты свидетельствуют о том, что добавка глюкозамина может служить эффективной альтернативой для симптоматического лечения ОА.
Данная статья публикуется в журнале Consilium Medicum на русском языке с разрешения правообладателей. Исходная статья: Puce M, Medne-Simsone A, Sprudza K. Prospective Short-Term Observational Study of Glucosamine Complex with Chondroprotectors Effect in Adults with Diagnosed Knee and/or Hip Osteoarthritis. Health 2025;17:405-424. doi: 10.4236/health.2025.174027 распространяется на условиях лицензии CC BY 4.0.
Ключевые слова: остеоартрит коленного сустава, хондропротекция, глюкозамин, хондроитин, жирные кислоты омега-3, гиалуроновая кислота, коллаген II типа
Materials and methods. A prospective observational study recruited 200 OA patients from family physician practices in Latvia. Patients were divided into 1) Study group (n=100) receiving Artroveron® 5in1 COMPLEX WITH OMEGA-3 (Glucosamine hydrochloride 300 mg, Omega-3 fatty acids 100 mg, Chondroitin sulfate 50 mg, Hyaluronic acid 20 mg, Type II collagen 20 mg); 2) Control group (n=100) receiving no chondroprotectors. Pain levels were assessed at baseline and after 30 days using: Western Ontario and McMaster Universities Arthritis Index (WOMAC), Visual Analogue Scale (VAS).
Results. Study group (glucosamine complex) had a statistically significant reduction in pain scores compared to the control group (p<0.001). WOMAC pain score decreased from 7.3±3.8 to 6.0±3.6 (p<0.001). WOMAC stiffness score improved from 3.4±1.7 to 2.6±1.8 (p<0.001). WOMAC difficulty score reduced from 26.6±11.3 to 21.0±11.5 (p<0.001). VAS pain score decreased from 5.8±1.6 to 4.9±1.5 in the study group, compared to 4.8±1.8 to 4.2±2.0 in controls (p<0.001).
Conclusion. Shortterm supplementation with Artroveron® 5in1 COMPLEX WITH OMEGA-3 significantly reduced OA pain and stiffness compared to untreated control group. These findings suggest that glucosamine supplementation may serve as an effective alternative for OA symptom management.
This article is published in the journal Consilium Medicum in Russian with the permission of the copyright holders. The original article: Puce M, Medne-Simsone A, Sprudza K. Prospective Short-Term Observational Study of Glucosamine Complex with Chondroprotectors Effect in Adults with Diagnosed Knee and/or Hip Osteoarthritis. Health 2025;17:405-424. doi: 10.4236/health.2025.174027 is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Keywords: knee osteoarthritis, chondroprotection, glucosamine, chondroitin, omega-3 fatty acids, hyaluronic acid, collagen type 2
Материалы и методы. В проспективном наблюдательном исследовании приняли участие 200 пациентов с ОА, наблюдаемых у семейных врачей в Латвии. Пациенты были разделены на: 1) исследуемую группу (n=100), получавшую Артроверон® 5в1 КОМПЛЕКС С ОМЕГА-3 (глюкозамина гидрохлорид 300 мг, омега-3 жирные кислоты 100 мг, хондроитина сульфат 50 мг, гиалуроновая кислота 20 мг, коллаген II типа 20 мг); 2) контрольную группу (n=100), не получавшую хондропротекторы. Уровень боли оценивали на исходном уровне и через 30 дней с использованием: индекса ОА университетов Западного Онтарио и Макмастера (WOMAC), Визуальной аналоговой шкалы.
Результаты. В исследуемой группе (принимавшей глюкозаминовый комплекс) отмечено статистически значимое снижение показателей боли по сравнению с контрольной группой (p<0,001). Оценка боли по WOMAC снизилась с 7,3±3,8 до 6,0±3,6 (p<0,001). Оценка скованности по WOMAC улучшилась с 3,4±1,7 до 2,6±1,8 (p<0,001). Оценка затрудненности движений по WOMAC снизилась с 26,6±11,3 до 21,0±11,5 (p<0,001). Оценка боли по Визуальной аналоговой шкале снизилась с 5,8±1,6 до 4,9±1,5 в исследуемой группе, а в контрольной группе – с 4,8±1,8 до 4,2±2,0 (p<0,001).
Заключение. Краткосрочное применение добавки Артроверон® 5в1 КОМПЛЕКС С ОМЕГА-3 значительно уменьшило боль и скованность при ОА по сравнению с контрольной группой, не получавшей лечения. Эти результаты свидетельствуют о том, что добавка глюкозамина может служить эффективной альтернативой для симптоматического лечения ОА.
Данная статья публикуется в журнале Consilium Medicum на русском языке с разрешения правообладателей. Исходная статья: Puce M, Medne-Simsone A, Sprudza K. Prospective Short-Term Observational Study of Glucosamine Complex with Chondroprotectors Effect in Adults with Diagnosed Knee and/or Hip Osteoarthritis. Health 2025;17:405-424. doi: 10.4236/health.2025.174027 распространяется на условиях лицензии CC BY 4.0.
Ключевые слова: остеоартрит коленного сустава, хондропротекция, глюкозамин, хондроитин, жирные кислоты омега-3, гиалуроновая кислота, коллаген II типа
________________________________________________
Materials and methods. A prospective observational study recruited 200 OA patients from family physician practices in Latvia. Patients were divided into 1) Study group (n=100) receiving Artroveron® 5in1 COMPLEX WITH OMEGA-3 (Glucosamine hydrochloride 300 mg, Omega-3 fatty acids 100 mg, Chondroitin sulfate 50 mg, Hyaluronic acid 20 mg, Type II collagen 20 mg); 2) Control group (n=100) receiving no chondroprotectors. Pain levels were assessed at baseline and after 30 days using: Western Ontario and McMaster Universities Arthritis Index (WOMAC), Visual Analogue Scale (VAS).
Results. Study group (glucosamine complex) had a statistically significant reduction in pain scores compared to the control group (p<0.001). WOMAC pain score decreased from 7.3±3.8 to 6.0±3.6 (p<0.001). WOMAC stiffness score improved from 3.4±1.7 to 2.6±1.8 (p<0.001). WOMAC difficulty score reduced from 26.6±11.3 to 21.0±11.5 (p<0.001). VAS pain score decreased from 5.8±1.6 to 4.9±1.5 in the study group, compared to 4.8±1.8 to 4.2±2.0 in controls (p<0.001).
Conclusion. Shortterm supplementation with Artroveron® 5in1 COMPLEX WITH OMEGA-3 significantly reduced OA pain and stiffness compared to untreated control group. These findings suggest that glucosamine supplementation may serve as an effective alternative for OA symptom management.
This article is published in the journal Consilium Medicum in Russian with the permission of the copyright holders. The original article: Puce M, Medne-Simsone A, Sprudza K. Prospective Short-Term Observational Study of Glucosamine Complex with Chondroprotectors Effect in Adults with Diagnosed Knee and/or Hip Osteoarthritis. Health 2025;17:405-424. doi: 10.4236/health.2025.174027 is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Keywords: knee osteoarthritis, chondroprotection, glucosamine, chondroitin, omega-3 fatty acids, hyaluronic acid, collagen type 2
Полный текст
Список литературы
1. Coaccioli S, Sarzi-Puttini P, Zis P, et al. Osteoarthritis: New Insight on Its Pathophysiology. J Clinl Med. 2022;11(20):6013. DOI:10.3390/jcm11206013
2. Anandacoomarasamy A, March L. Current Evidence for Osteoarthritis Treatments. Ther Adv Musculoskelet Dis. 2010;2(1):17-28. DOI:10.1177/1759720x09359889
3. Sukhikh S, Babich O, Prosekov A, et al. Future of Chondroprotectors in the Treatment of Degenerative Processes of Connective Tissue. Pharmaceuticals (Basel). 2020;13(9):220. DOI:10.3390/ph13090220
4. Zhu X, Sang L, Wu D, et al. Effectiveness and Safety of Glucosamine and Chondroitin for the Treatment of Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. J Orthop Surg Res. 2018;13(1):170. DOI:10.1186/s13018-018-0871-5
5. Honvo G, Reginster J, Rabenda V, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36:65-99. DOI:10.1007/s40266-019-00662-z
6. Arden NK, Perry TA, Bannuru RR, et al. Non-Surgical Management of Knee Osteoarthritis: Comparison of ESCEO and OARSI 2019 Guidelines. Nat Rev Rheumatol. 2021:17(1):59-66. DOI:10.1038/s41584-020-00523-9
7. Téllez Méndez R, Cabeza L, González Yibirin M, et al. Randomized, Double-Blind, Double-Masked, Parallel Group Clinical Study to Compare the Effectiveness of Diclofenac Potassium 150 Mg, LP OD, vs Diclofenac Potassium 50 Mg, TID, Three Times a Day, in Knee Osteoarthritis. Int J Clin Med. 2023;14:239-49. DOI:10.4236/ijcm.2023.145020
8. Wang Y, Li D, Lv Z, et al. Efficacy and Safety of Gutong Patch Compared with Nsaids for Knee Osteoarthritis: A Real-World Multicenter, Prospective Cohort Study in China. Pharmacol Res. 2023;197:106954. DOI:10.1016/j.phrs.2023.106954
9. Fox B. Glucosamine Hydrochloride for the Treatment of Osteoarthritis Symptoms. Clin Interv Aging. 2007;2(4):599-604. DOI:10.2147/cia.s1632
10. Migliore A. Effectiveness and Utility of Hyaluronic Acid in Osteoarthritis. Clinl Cases Miner Bone Metab. 2015;12(1):31-3. DOI:10.11138/ccmbm/2015.12.1.031
11. Materkowski M. Efficacy Treatment of Osteoarthritis with Combine Chondroitin and Glucosamine. Ortop Traumatol Rehabil. 2021;23(3):239-44. DOI:10.5604/01.3001.0014.9842
12. Vasiliadis HS, Tsikopoulos K. Glucosamine and Chondroitin for the Treatment of Osteoarthritis. World J Orthop. 2017;8(1):1-11. DOI:10.5312/wjo.v8.i1.1
13. Gupta RC, Lall R, Srivastava A, Sinha A. Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory. Front Vet Sci. 2019;6:192. DOI:10.3389/fvets.2019.00192
14. Bakilan F, Armagan O, Ozgen M, et al. Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial. Eurasian J Med. 2016;48(2):95-101. DOI:10.5152/eurasianjmed.2015.15030
15. Cordingley DM, Cornish SM. Omega-3 Fatty Acids for the Management of Osteoarthritis: A Narrative Review. Nutrients. 2022;14(16):3362. DOI:10.3390/nu14163362
16. Meng Z, Liu J, Zhou N. Efficacy and Safety of the Combination of Glucosamine and Chondroitin for Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Arch Orthop Trauma Surg. 2023;143(1):409-21. DOI:10.1007/s00402-021-04326-9
17. Heller GZ, Manuguerra M, Chow R. How to Analyze the Visual Analogue Scale: Myths, Truths and Clinical Relevance. Scand J Pain. 2016;13:67-75. DOI:10.1016/j.sjpain.2016.06.012
18. Silva MDC, Perriman DM, Fearon AM, et al. Minimal Important Change and Difference for Knee Osteoarthritis Outcome Measurement Tools after Non-Surgical Interventions: A Systematic Review. BMJ Open. 2023;13(5):e063026. DOI:10.1136/bmjopen-2022-063026
19. Clement ND, Bardgett M, Weir D, et al. What Is the Minimum Clinically Important Difference for the WOMAC Index after TKA? Clin Orthop Relat Res. 2018;476(10):2005-14. DOI:10.1097/corr.0000000000000444
20. Olaiya OR, Abraha B, Gallo L, et al. Estimating the Minimal Clinically Important Difference on the Visual Analogue Scale for Carpometacarpal Thumb Joint Osteoarthritis. HAND. 2025;20(5):720-4. DOI:10.1177/15589447241235344
21. Sumsuzzman DM, Khan ZA, Jung JH, et al. Comparative Efficacy of Glucosamine-Based Combination Therapies in Alleviating Knee Osteoarthritis Pain: A Systematic Review and Network Meta-Analysis. J Clin Med. 2024;13(23):7444. DOI:10.3390/jcm13237444
22. Varagani DS, Kumar DMU, Ahamad T, et al. Role of Glucosamine and Hyaluronic Acid in the Treatment of Osteoarthritis. Int J Advanc Res Biol Sci. 2024;11(7):112-26. DOI:10.22192/ijarbs.2024.11.07.011
23. Jerosch J. Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids. Int J Rheumatol. 2011;2011:969012. DOI:10.1155/2011/969012
24. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. New Engl J Med. 2006;354(8):795-808. DOI:10.1056/nejmoa052771
25. Čeh T, Šarabon N. Effects of Adding Glucosamine or Glucosamine Combined with Chondroitin to Exercise on Pain and Physical Function in Adults with Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Eur J Transl Myol. 2023;33(4):12013. DOI:10.4081/ejtm.2023.12013
26. Sconza C, Romano D, Scaturro D, et al. Safety and Efficacy of Hybrid Cooperative Complexes of Sodium Hyaluronate and Sodium Chondroitin for the Treatment of Patients with Symptomatic Knee Osteoarthritis. Rheumatol Ther. 2024;11:381-95. DOI:10.1007/s40744-024-00643-8
27. Price D, Staud R, Robinson M. How Should We Use the Visual Analogue Scale (VAS) in Rehabilitation Outcomes? II: Visual Analogue Scales as Ratio Scales: An Alternative to the View of Kersten et al. J Rehabil Med. 2012;44:800-1. DOI:10.2340/16501977-1031
28. Neogi T. The Epidemiology and Impact of Pain in Osteoarthritis. Osteoarthritis Cartilage. 2013;21(9):1145-53. DOI:10.1016/j.joca.2013.03.018
29. Kim C, Nevitt MC, Niu J, et al. Association of Hip Pain with Radiographic Evidence of Hip Osteoarthritis: Diagnostic Test Study. BMJ. 2015;351:h5983. DOI:10.1136/bmj.h5983
30. Slayton MH, Baravarian B, Amodei RC, et al. Intense Therapeutic Ultrasound for Pain Relief in the Treatment for Chronic Plantar Fasciopathy. Foot Ankle Orthop. 2019;4(3):1-8. DOI:10.1177/2473011419862228
31. Zhang Y, Chen T, Luo P, et al. Associations of Dietary Macroelements with Knee Joint Structures, Symptoms, Quality of Life, and Comorbid Conditions in People with Symptomatic Knee Osteoarthritis. Nutrients. 2022;14(17):3576. DOI:10.3390/nu14173576
32. Dobson F, Hinman RS, Hall M, et al. Measurement Properties of Performance-Based Measures to Assess Physical Function in Hip and Knee Osteoarthritis: A Systematic Review. Osteoarthritis Cartilage. 2012;20(12):1548-62. DOI:10.1016/j.joca.2012.08.015
33. Whittaker JL, Truong LK, Dhiman K, Beck C. Osteoarthritis Year in Review 2020: Rehabilitation and Outcomes. Osteoarthritis Cartilage. 2021;29(2):190-207. DOI:10.1016/j.joca.2020.10.005
34. Tubach F, Baron G, Falissard B, et al. Using Patients’ and Rheumatologists’ Opinions to Specify a Short Form of the WOMAC Function Subscale. Ann Rheum Diseas. 2005;64(1):75-9. DOI:10.1136/ard.2003.019539
2. Anandacoomarasamy A, March L. Current Evidence for Osteoarthritis Treatments. Ther Adv Musculoskelet Dis. 2010;2(1):17-28. DOI:10.1177/1759720x09359889
3. Sukhikh S, Babich O, Prosekov A, et al. Future of Chondroprotectors in the Treatment of Degenerative Processes of Connective Tissue. Pharmaceuticals (Basel). 2020;13(9):220. DOI:10.3390/ph13090220
4. Zhu X, Sang L, Wu D, et al. Effectiveness and Safety of Glucosamine and Chondroitin for the Treatment of Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. J Orthop Surg Res. 2018;13(1):170. DOI:10.1186/s13018-018-0871-5
5. Honvo G, Reginster J, Rabenda V, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36:65-99. DOI:10.1007/s40266-019-00662-z
6. Arden NK, Perry TA, Bannuru RR, et al. Non-Surgical Management of Knee Osteoarthritis: Comparison of ESCEO and OARSI 2019 Guidelines. Nat Rev Rheumatol. 2021:17(1):59-66. DOI:10.1038/s41584-020-00523-9
7. Téllez Méndez R, Cabeza L, González Yibirin M, et al. Randomized, Double-Blind, Double-Masked, Parallel Group Clinical Study to Compare the Effectiveness of Diclofenac Potassium 150 Mg, LP OD, vs Diclofenac Potassium 50 Mg, TID, Three Times a Day, in Knee Osteoarthritis. Int J Clin Med. 2023;14:239-49. DOI:10.4236/ijcm.2023.145020
8. Wang Y, Li D, Lv Z, et al. Efficacy and Safety of Gutong Patch Compared with Nsaids for Knee Osteoarthritis: A Real-World Multicenter, Prospective Cohort Study in China. Pharmacol Res. 2023;197:106954. DOI:10.1016/j.phrs.2023.106954
9. Fox B. Glucosamine Hydrochloride for the Treatment of Osteoarthritis Symptoms. Clin Interv Aging. 2007;2(4):599-604. DOI:10.2147/cia.s1632
10. Migliore A. Effectiveness and Utility of Hyaluronic Acid in Osteoarthritis. Clinl Cases Miner Bone Metab. 2015;12(1):31-3. DOI:10.11138/ccmbm/2015.12.1.031
11. Materkowski M. Efficacy Treatment of Osteoarthritis with Combine Chondroitin and Glucosamine. Ortop Traumatol Rehabil. 2021;23(3):239-44. DOI:10.5604/01.3001.0014.9842
12. Vasiliadis HS, Tsikopoulos K. Glucosamine and Chondroitin for the Treatment of Osteoarthritis. World J Orthop. 2017;8(1):1-11. DOI:10.5312/wjo.v8.i1.1
13. Gupta RC, Lall R, Srivastava A, Sinha A. Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory. Front Vet Sci. 2019;6:192. DOI:10.3389/fvets.2019.00192
14. Bakilan F, Armagan O, Ozgen M, et al. Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial. Eurasian J Med. 2016;48(2):95-101. DOI:10.5152/eurasianjmed.2015.15030
15. Cordingley DM, Cornish SM. Omega-3 Fatty Acids for the Management of Osteoarthritis: A Narrative Review. Nutrients. 2022;14(16):3362. DOI:10.3390/nu14163362
16. Meng Z, Liu J, Zhou N. Efficacy and Safety of the Combination of Glucosamine and Chondroitin for Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Arch Orthop Trauma Surg. 2023;143(1):409-21. DOI:10.1007/s00402-021-04326-9
17. Heller GZ, Manuguerra M, Chow R. How to Analyze the Visual Analogue Scale: Myths, Truths and Clinical Relevance. Scand J Pain. 2016;13:67-75. DOI:10.1016/j.sjpain.2016.06.012
18. Silva MDC, Perriman DM, Fearon AM, et al. Minimal Important Change and Difference for Knee Osteoarthritis Outcome Measurement Tools after Non-Surgical Interventions: A Systematic Review. BMJ Open. 2023;13(5):e063026. DOI:10.1136/bmjopen-2022-063026
19. Clement ND, Bardgett M, Weir D, et al. What Is the Minimum Clinically Important Difference for the WOMAC Index after TKA? Clin Orthop Relat Res. 2018;476(10):2005-14. DOI:10.1097/corr.0000000000000444
20. Olaiya OR, Abraha B, Gallo L, et al. Estimating the Minimal Clinically Important Difference on the Visual Analogue Scale for Carpometacarpal Thumb Joint Osteoarthritis. HAND. 2025;20(5):720-4. DOI:10.1177/15589447241235344
21. Sumsuzzman DM, Khan ZA, Jung JH, et al. Comparative Efficacy of Glucosamine-Based Combination Therapies in Alleviating Knee Osteoarthritis Pain: A Systematic Review and Network Meta-Analysis. J Clin Med. 2024;13(23):7444. DOI:10.3390/jcm13237444
22. Varagani DS, Kumar DMU, Ahamad T, et al. Role of Glucosamine and Hyaluronic Acid in the Treatment of Osteoarthritis. Int J Advanc Res Biol Sci. 2024;11(7):112-26. DOI:10.22192/ijarbs.2024.11.07.011
23. Jerosch J. Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids. Int J Rheumatol. 2011;2011:969012. DOI:10.1155/2011/969012
24. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. New Engl J Med. 2006;354(8):795-808. DOI:10.1056/nejmoa052771
25. Čeh T, Šarabon N. Effects of Adding Glucosamine or Glucosamine Combined with Chondroitin to Exercise on Pain and Physical Function in Adults with Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Eur J Transl Myol. 2023;33(4):12013. DOI:10.4081/ejtm.2023.12013
26. Sconza C, Romano D, Scaturro D, et al. Safety and Efficacy of Hybrid Cooperative Complexes of Sodium Hyaluronate and Sodium Chondroitin for the Treatment of Patients with Symptomatic Knee Osteoarthritis. Rheumatol Ther. 2024;11:381-95. DOI:10.1007/s40744-024-00643-8
27. Price D, Staud R, Robinson M. How Should We Use the Visual Analogue Scale (VAS) in Rehabilitation Outcomes? II: Visual Analogue Scales as Ratio Scales: An Alternative to the View of Kersten et al. J Rehabil Med. 2012;44:800-1. DOI:10.2340/16501977-1031
28. Neogi T. The Epidemiology and Impact of Pain in Osteoarthritis. Osteoarthritis Cartilage. 2013;21(9):1145-53. DOI:10.1016/j.joca.2013.03.018
29. Kim C, Nevitt MC, Niu J, et al. Association of Hip Pain with Radiographic Evidence of Hip Osteoarthritis: Diagnostic Test Study. BMJ. 2015;351:h5983. DOI:10.1136/bmj.h5983
30. Slayton MH, Baravarian B, Amodei RC, et al. Intense Therapeutic Ultrasound for Pain Relief in the Treatment for Chronic Plantar Fasciopathy. Foot Ankle Orthop. 2019;4(3):1-8. DOI:10.1177/2473011419862228
31. Zhang Y, Chen T, Luo P, et al. Associations of Dietary Macroelements with Knee Joint Structures, Symptoms, Quality of Life, and Comorbid Conditions in People with Symptomatic Knee Osteoarthritis. Nutrients. 2022;14(17):3576. DOI:10.3390/nu14173576
32. Dobson F, Hinman RS, Hall M, et al. Measurement Properties of Performance-Based Measures to Assess Physical Function in Hip and Knee Osteoarthritis: A Systematic Review. Osteoarthritis Cartilage. 2012;20(12):1548-62. DOI:10.1016/j.joca.2012.08.015
33. Whittaker JL, Truong LK, Dhiman K, Beck C. Osteoarthritis Year in Review 2020: Rehabilitation and Outcomes. Osteoarthritis Cartilage. 2021;29(2):190-207. DOI:10.1016/j.joca.2020.10.005
34. Tubach F, Baron G, Falissard B, et al. Using Patients’ and Rheumatologists’ Opinions to Specify a Short Form of the WOMAC Function Subscale. Ann Rheum Diseas. 2005;64(1):75-9. DOI:10.1136/ard.2003.019539
2. Anandacoomarasamy A, March L. Current Evidence for Osteoarthritis Treatments. Ther Adv Musculoskelet Dis. 2010;2(1):17-28. DOI:10.1177/1759720x09359889
3. Sukhikh S, Babich O, Prosekov A, et al. Future of Chondroprotectors in the Treatment of Degenerative Processes of Connective Tissue. Pharmaceuticals (Basel). 2020;13(9):220. DOI:10.3390/ph13090220
4. Zhu X, Sang L, Wu D, et al. Effectiveness and Safety of Glucosamine and Chondroitin for the Treatment of Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. J Orthop Surg Res. 2018;13(1):170. DOI:10.1186/s13018-018-0871-5
5. Honvo G, Reginster J, Rabenda V, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36:65-99. DOI:10.1007/s40266-019-00662-z
6. Arden NK, Perry TA, Bannuru RR, et al. Non-Surgical Management of Knee Osteoarthritis: Comparison of ESCEO and OARSI 2019 Guidelines. Nat Rev Rheumatol. 2021:17(1):59-66. DOI:10.1038/s41584-020-00523-9
7. Téllez Méndez R, Cabeza L, González Yibirin M, et al. Randomized, Double-Blind, Double-Masked, Parallel Group Clinical Study to Compare the Effectiveness of Diclofenac Potassium 150 Mg, LP OD, vs Diclofenac Potassium 50 Mg, TID, Three Times a Day, in Knee Osteoarthritis. Int J Clin Med. 2023;14:239-49. DOI:10.4236/ijcm.2023.145020
8. Wang Y, Li D, Lv Z, et al. Efficacy and Safety of Gutong Patch Compared with Nsaids for Knee Osteoarthritis: A Real-World Multicenter, Prospective Cohort Study in China. Pharmacol Res. 2023;197:106954. DOI:10.1016/j.phrs.2023.106954
9. Fox B. Glucosamine Hydrochloride for the Treatment of Osteoarthritis Symptoms. Clin Interv Aging. 2007;2(4):599-604. DOI:10.2147/cia.s1632
10. Migliore A. Effectiveness and Utility of Hyaluronic Acid in Osteoarthritis. Clinl Cases Miner Bone Metab. 2015;12(1):31-3. DOI:10.11138/ccmbm/2015.12.1.031
11. Materkowski M. Efficacy Treatment of Osteoarthritis with Combine Chondroitin and Glucosamine. Ortop Traumatol Rehabil. 2021;23(3):239-44. DOI:10.5604/01.3001.0014.9842
12. Vasiliadis HS, Tsikopoulos K. Glucosamine and Chondroitin for the Treatment of Osteoarthritis. World J Orthop. 2017;8(1):1-11. DOI:10.5312/wjo.v8.i1.1
13. Gupta RC, Lall R, Srivastava A, Sinha A. Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory. Front Vet Sci. 2019;6:192. DOI:10.3389/fvets.2019.00192
14. Bakilan F, Armagan O, Ozgen M, et al. Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial. Eurasian J Med. 2016;48(2):95-101. DOI:10.5152/eurasianjmed.2015.15030
15. Cordingley DM, Cornish SM. Omega-3 Fatty Acids for the Management of Osteoarthritis: A Narrative Review. Nutrients. 2022;14(16):3362. DOI:10.3390/nu14163362
16. Meng Z, Liu J, Zhou N. Efficacy and Safety of the Combination of Glucosamine and Chondroitin for Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Arch Orthop Trauma Surg. 2023;143(1):409-21. DOI:10.1007/s00402-021-04326-9
17. Heller GZ, Manuguerra M, Chow R. How to Analyze the Visual Analogue Scale: Myths, Truths and Clinical Relevance. Scand J Pain. 2016;13:67-75. DOI:10.1016/j.sjpain.2016.06.012
18. Silva MDC, Perriman DM, Fearon AM, et al. Minimal Important Change and Difference for Knee Osteoarthritis Outcome Measurement Tools after Non-Surgical Interventions: A Systematic Review. BMJ Open. 2023;13(5):e063026. DOI:10.1136/bmjopen-2022-063026
19. Clement ND, Bardgett M, Weir D, et al. What Is the Minimum Clinically Important Difference for the WOMAC Index after TKA? Clin Orthop Relat Res. 2018;476(10):2005-14. DOI:10.1097/corr.0000000000000444
20. Olaiya OR, Abraha B, Gallo L, et al. Estimating the Minimal Clinically Important Difference on the Visual Analogue Scale for Carpometacarpal Thumb Joint Osteoarthritis. HAND. 2025;20(5):720-4. DOI:10.1177/15589447241235344
21. Sumsuzzman DM, Khan ZA, Jung JH, et al. Comparative Efficacy of Glucosamine-Based Combination Therapies in Alleviating Knee Osteoarthritis Pain: A Systematic Review and Network Meta-Analysis. J Clin Med. 2024;13(23):7444. DOI:10.3390/jcm13237444
22. Varagani DS, Kumar DMU, Ahamad T, et al. Role of Glucosamine and Hyaluronic Acid in the Treatment of Osteoarthritis. Int J Advanc Res Biol Sci. 2024;11(7):112-26. DOI:10.22192/ijarbs.2024.11.07.011
23. Jerosch J. Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids. Int J Rheumatol. 2011;2011:969012. DOI:10.1155/2011/969012
24. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. New Engl J Med. 2006;354(8):795-808. DOI:10.1056/nejmoa052771
25. Čeh T, Šarabon N. Effects of Adding Glucosamine or Glucosamine Combined with Chondroitin to Exercise on Pain and Physical Function in Adults with Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Eur J Transl Myol. 2023;33(4):12013. DOI:10.4081/ejtm.2023.12013
26. Sconza C, Romano D, Scaturro D, et al. Safety and Efficacy of Hybrid Cooperative Complexes of Sodium Hyaluronate and Sodium Chondroitin for the Treatment of Patients with Symptomatic Knee Osteoarthritis. Rheumatol Ther. 2024;11:381-95. DOI:10.1007/s40744-024-00643-8
27. Price D, Staud R, Robinson M. How Should We Use the Visual Analogue Scale (VAS) in Rehabilitation Outcomes? II: Visual Analogue Scales as Ratio Scales: An Alternative to the View of Kersten et al. J Rehabil Med. 2012;44:800-1. DOI:10.2340/16501977-1031
28. Neogi T. The Epidemiology and Impact of Pain in Osteoarthritis. Osteoarthritis Cartilage. 2013;21(9):1145-53. DOI:10.1016/j.joca.2013.03.018
29. Kim C, Nevitt MC, Niu J, et al. Association of Hip Pain with Radiographic Evidence of Hip Osteoarthritis: Diagnostic Test Study. BMJ. 2015;351:h5983. DOI:10.1136/bmj.h5983
30. Slayton MH, Baravarian B, Amodei RC, et al. Intense Therapeutic Ultrasound for Pain Relief in the Treatment for Chronic Plantar Fasciopathy. Foot Ankle Orthop. 2019;4(3):1-8. DOI:10.1177/2473011419862228
31. Zhang Y, Chen T, Luo P, et al. Associations of Dietary Macroelements with Knee Joint Structures, Symptoms, Quality of Life, and Comorbid Conditions in People with Symptomatic Knee Osteoarthritis. Nutrients. 2022;14(17):3576. DOI:10.3390/nu14173576
32. Dobson F, Hinman RS, Hall M, et al. Measurement Properties of Performance-Based Measures to Assess Physical Function in Hip and Knee Osteoarthritis: A Systematic Review. Osteoarthritis Cartilage. 2012;20(12):1548-62. DOI:10.1016/j.joca.2012.08.015
33. Whittaker JL, Truong LK, Dhiman K, Beck C. Osteoarthritis Year in Review 2020: Rehabilitation and Outcomes. Osteoarthritis Cartilage. 2021;29(2):190-207. DOI:10.1016/j.joca.2020.10.005
34. Tubach F, Baron G, Falissard B, et al. Using Patients’ and Rheumatologists’ Opinions to Specify a Short Form of the WOMAC Function Subscale. Ann Rheum Diseas. 2005;64(1):75-9. DOI:10.1136/ard.2003.019539
________________________________________________
2. Anandacoomarasamy A, March L. Current Evidence for Osteoarthritis Treatments. Ther Adv Musculoskelet Dis. 2010;2(1):17-28. DOI:10.1177/1759720x09359889
3. Sukhikh S, Babich O, Prosekov A, et al. Future of Chondroprotectors in the Treatment of Degenerative Processes of Connective Tissue. Pharmaceuticals (Basel). 2020;13(9):220. DOI:10.3390/ph13090220
4. Zhu X, Sang L, Wu D, et al. Effectiveness and Safety of Glucosamine and Chondroitin for the Treatment of Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. J Orthop Surg Res. 2018;13(1):170. DOI:10.1186/s13018-018-0871-5
5. Honvo G, Reginster J, Rabenda V, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36:65-99. DOI:10.1007/s40266-019-00662-z
6. Arden NK, Perry TA, Bannuru RR, et al. Non-Surgical Management of Knee Osteoarthritis: Comparison of ESCEO and OARSI 2019 Guidelines. Nat Rev Rheumatol. 2021:17(1):59-66. DOI:10.1038/s41584-020-00523-9
7. Téllez Méndez R, Cabeza L, González Yibirin M, et al. Randomized, Double-Blind, Double-Masked, Parallel Group Clinical Study to Compare the Effectiveness of Diclofenac Potassium 150 Mg, LP OD, vs Diclofenac Potassium 50 Mg, TID, Three Times a Day, in Knee Osteoarthritis. Int J Clin Med. 2023;14:239-49. DOI:10.4236/ijcm.2023.145020
8. Wang Y, Li D, Lv Z, et al. Efficacy and Safety of Gutong Patch Compared with Nsaids for Knee Osteoarthritis: A Real-World Multicenter, Prospective Cohort Study in China. Pharmacol Res. 2023;197:106954. DOI:10.1016/j.phrs.2023.106954
9. Fox B. Glucosamine Hydrochloride for the Treatment of Osteoarthritis Symptoms. Clin Interv Aging. 2007;2(4):599-604. DOI:10.2147/cia.s1632
10. Migliore A. Effectiveness and Utility of Hyaluronic Acid in Osteoarthritis. Clinl Cases Miner Bone Metab. 2015;12(1):31-3. DOI:10.11138/ccmbm/2015.12.1.031
11. Materkowski M. Efficacy Treatment of Osteoarthritis with Combine Chondroitin and Glucosamine. Ortop Traumatol Rehabil. 2021;23(3):239-44. DOI:10.5604/01.3001.0014.9842
12. Vasiliadis HS, Tsikopoulos K. Glucosamine and Chondroitin for the Treatment of Osteoarthritis. World J Orthop. 2017;8(1):1-11. DOI:10.5312/wjo.v8.i1.1
13. Gupta RC, Lall R, Srivastava A, Sinha A. Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory. Front Vet Sci. 2019;6:192. DOI:10.3389/fvets.2019.00192
14. Bakilan F, Armagan O, Ozgen M, et al. Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial. Eurasian J Med. 2016;48(2):95-101. DOI:10.5152/eurasianjmed.2015.15030
15. Cordingley DM, Cornish SM. Omega-3 Fatty Acids for the Management of Osteoarthritis: A Narrative Review. Nutrients. 2022;14(16):3362. DOI:10.3390/nu14163362
16. Meng Z, Liu J, Zhou N. Efficacy and Safety of the Combination of Glucosamine and Chondroitin for Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Arch Orthop Trauma Surg. 2023;143(1):409-21. DOI:10.1007/s00402-021-04326-9
17. Heller GZ, Manuguerra M, Chow R. How to Analyze the Visual Analogue Scale: Myths, Truths and Clinical Relevance. Scand J Pain. 2016;13:67-75. DOI:10.1016/j.sjpain.2016.06.012
18. Silva MDC, Perriman DM, Fearon AM, et al. Minimal Important Change and Difference for Knee Osteoarthritis Outcome Measurement Tools after Non-Surgical Interventions: A Systematic Review. BMJ Open. 2023;13(5):e063026. DOI:10.1136/bmjopen-2022-063026
19. Clement ND, Bardgett M, Weir D, et al. What Is the Minimum Clinically Important Difference for the WOMAC Index after TKA? Clin Orthop Relat Res. 2018;476(10):2005-14. DOI:10.1097/corr.0000000000000444
20. Olaiya OR, Abraha B, Gallo L, et al. Estimating the Minimal Clinically Important Difference on the Visual Analogue Scale for Carpometacarpal Thumb Joint Osteoarthritis. HAND. 2025;20(5):720-4. DOI:10.1177/15589447241235344
21. Sumsuzzman DM, Khan ZA, Jung JH, et al. Comparative Efficacy of Glucosamine-Based Combination Therapies in Alleviating Knee Osteoarthritis Pain: A Systematic Review and Network Meta-Analysis. J Clin Med. 2024;13(23):7444. DOI:10.3390/jcm13237444
22. Varagani DS, Kumar DMU, Ahamad T, et al. Role of Glucosamine and Hyaluronic Acid in the Treatment of Osteoarthritis. Int J Advanc Res Biol Sci. 2024;11(7):112-26. DOI:10.22192/ijarbs.2024.11.07.011
23. Jerosch J. Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids. Int J Rheumatol. 2011;2011:969012. DOI:10.1155/2011/969012
24. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. New Engl J Med. 2006;354(8):795-808. DOI:10.1056/nejmoa052771
25. Čeh T, Šarabon N. Effects of Adding Glucosamine or Glucosamine Combined with Chondroitin to Exercise on Pain and Physical Function in Adults with Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Eur J Transl Myol. 2023;33(4):12013. DOI:10.4081/ejtm.2023.12013
26. Sconza C, Romano D, Scaturro D, et al. Safety and Efficacy of Hybrid Cooperative Complexes of Sodium Hyaluronate and Sodium Chondroitin for the Treatment of Patients with Symptomatic Knee Osteoarthritis. Rheumatol Ther. 2024;11:381-95. DOI:10.1007/s40744-024-00643-8
27. Price D, Staud R, Robinson M. How Should We Use the Visual Analogue Scale (VAS) in Rehabilitation Outcomes? II: Visual Analogue Scales as Ratio Scales: An Alternative to the View of Kersten et al. J Rehabil Med. 2012;44:800-1. DOI:10.2340/16501977-1031
28. Neogi T. The Epidemiology and Impact of Pain in Osteoarthritis. Osteoarthritis Cartilage. 2013;21(9):1145-53. DOI:10.1016/j.joca.2013.03.018
29. Kim C, Nevitt MC, Niu J, et al. Association of Hip Pain with Radiographic Evidence of Hip Osteoarthritis: Diagnostic Test Study. BMJ. 2015;351:h5983. DOI:10.1136/bmj.h5983
30. Slayton MH, Baravarian B, Amodei RC, et al. Intense Therapeutic Ultrasound for Pain Relief in the Treatment for Chronic Plantar Fasciopathy. Foot Ankle Orthop. 2019;4(3):1-8. DOI:10.1177/2473011419862228
31. Zhang Y, Chen T, Luo P, et al. Associations of Dietary Macroelements with Knee Joint Structures, Symptoms, Quality of Life, and Comorbid Conditions in People with Symptomatic Knee Osteoarthritis. Nutrients. 2022;14(17):3576. DOI:10.3390/nu14173576
32. Dobson F, Hinman RS, Hall M, et al. Measurement Properties of Performance-Based Measures to Assess Physical Function in Hip and Knee Osteoarthritis: A Systematic Review. Osteoarthritis Cartilage. 2012;20(12):1548-62. DOI:10.1016/j.joca.2012.08.015
33. Whittaker JL, Truong LK, Dhiman K, Beck C. Osteoarthritis Year in Review 2020: Rehabilitation and Outcomes. Osteoarthritis Cartilage. 2021;29(2):190-207. DOI:10.1016/j.joca.2020.10.005
34. Tubach F, Baron G, Falissard B, et al. Using Patients’ and Rheumatologists’ Opinions to Specify a Short Form of the WOMAC Function Subscale. Ann Rheum Diseas. 2005;64(1):75-9. DOI:10.1136/ard.2003.019539
Авторы
Maija Puce1, Anna Medne-Simsone2, Klinta Luize Sprudza3
1Dinas Puhartes Family Doctors Practice Ltd., Сигулда, Латвия
2Annas Mednes-Simsones Family Doctors Practice Ltd., Бауска, Латвия
3Медицинский факультет, Рижский университет имени Страдыня, Рига, Латвия
1Dinas Puhartes Family Doctors Practice Ltd., Sigulda, Latvia
2Annas Mednes-Simsones Family Doctors Practice Ltd., Bauska, Latvia
3Faculty of Medicine, Riga Stradins University, Riga, Latvia
1Dinas Puhartes Family Doctors Practice Ltd., Сигулда, Латвия
2Annas Mednes-Simsones Family Doctors Practice Ltd., Бауска, Латвия
3Медицинский факультет, Рижский университет имени Страдыня, Рига, Латвия
________________________________________________
1Dinas Puhartes Family Doctors Practice Ltd., Sigulda, Latvia
2Annas Mednes-Simsones Family Doctors Practice Ltd., Bauska, Latvia
3Faculty of Medicine, Riga Stradins University, Riga, Latvia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.